1.Adams EJ, Turner KM, Edmunds WJ. The cost effectiveness of opportunistic chlamydia screening in England. Sex Transm Infect. 2007;83:267–274.
2.Barham L, Lewis D, Latimer N. One to one interventions to reduce sexually transmitted infections and under the age of 18 conceptions: A systematic review of the economic evaluations. Sex Transm Infect. 2007;83:441–446.
3.Brown RE, Breugelmans JG, Theodoratou D, Benard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin. 2006;22:663–670.
4.Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14:244–251.
5.Chlamydia Advisory Group. The first steps. . . Annual report of the National Chlamydia Screening Programme in England. London: Department of Health; 2004:1–44.
6.Cohen DA, Wu SY, Farley TA. Comparing the cost-effectiveness of HIV prevention interventions (DARE structured abstract). J Acquir Immune Defic Syndr. 2004;37:1404–1414.
7.Curtis L, Netten A. Unit costs of health and social care. Canterbury, PSSRU, University of Kent; 2006.
8.Fisher M, Benn P, Evans B, et al.UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposure. Int J STD AIDS. 2006;17:81–92.
9.Health Protection Agency. Diagnoses and rates of selected STIs seen at UK GUM clinics by country and age group: 2002–2006. London: Health Protection Agency, Centre for Infections; 2007:1–33.
10.Health Protection Agency. Testing times HIV and other sexually transmitted infections in the United Kingdom. London: Health Protection Agency, Centre for Infections; 2007.
12.Hu D, Hook EW III, Goldie SJ. Screening for Chlamydia trachomatis in women 15 to 29 years of age: A cost-effectiveness analysis. Ann Intern Med. 2004;141:501–513.
13.Johnson AM, Mercer CH, Erens B, et al.Sexual behaviour in Britain: Partnerships, practices, and HIV risk behaviours. Lancet. 2001;358:1835–1842.
14.Lader D.Contraception and sexual health. Omnibus Survey Report No. 33. -108. Newport: Office of National Statistics; 2007.
15.Langley PC, White DJ, Drake SM. The costs of treating external genital warts in England and Wales: A treatment pattern analysis. Int J STD AIDS. 2004;15:501–508.
16.Low N, McCarthy A, Macleod J, et al.Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess. 2007;11:iii–xii, 1.
17.Miners AH, Sabin CA, Trueman P, et al.Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med. 2001;2:52–58.
18.NICE. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence; 2008.
19.Quinn TC, Gaydos C, Shepherd M, et al.Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. JAMA. 1996;276:1737–1742.
20.Rao GG, Bacon L, Evans J, et al.Prevalence of Neisseria gonorrhoeae infection in young subjects attending community clinics in South London. Sex Transm Infect. 2008;84:117–121.
21.Rothenberg R, Potterat JJ, Koplan JP. The algebra of condoms and abstinence. Sex Transm Dis. 2005;32:252–254.
22.Shepherd J, Kavanagh J, Picot J, et al.The effectiveness and cost-effectiveness of behavioural interventions for the prevention of sexually transmitted infections in young people aged 13–19: A systematic review and economic evaluation. Health Technol Assess. 2010;14:1-iv.
23.Smith KJ, Tsevat J, Ness RB, Wiesenfeld HC, Roberts MS. Quality of life utilities for pelvic inflammatory disease health States. Sex Transm Dis. 2008;35:307–311.
24.Stephenson JM, Strange V, Forrest S, et al.Pupil-led sex education in England (RIPPLE study): Cluster-randomised intervention trial. Lancet. 2004;364:338–346.
25.Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. [see comment]. Med Decis Making. 2002;22:475–481.
26.Wang LY, Davis M, Robin L, et al.Economic evaluation of safer choices: A school-based human immunodeficiency virus, other sexually transmitted diseases, and pregnancy prevention program. Arch Pediatr Adolesc Med. 2000;154:1017–1024.
27.Weatherly H, Drummond M, Claxton K, et al.Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations. Health Policy. 2009;93:85–92.
28.Weinstein M, Graham J, Siegel J. Cost effectiveness analysis of AIDS prevention programs: Concepts, complications, and illustrations. In: Turner C, Miller H, Moses L, eds. AIDS: Sexual behavior and intravenous drug use. Washington, DC: National Academy Press; 1989:471–499.
29.WHO. In: Currie C, Gabhainn S, Godeau E, Roberts C, Smith R, eds. Inequalities in young people's health. HBSC international report from the 2005/2006 survey. Copenhagen, Denmark: WHO; 2008:1–210.
30.Wight D, Raab GM, Henderson M, et al.Limits of teacher delivered sex education: Interim behavioural outcomes from randomised trial. BMJ. 2002;324:1430.
31.Wolstenholme JL, Whynes DK. Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer. 1998;34:1889–1893.